Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
crizotinib + temozolomide
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Crizotinib + temozolomide is an investigational combination therapy evaluated primarily for the treatment of newly diagnosed glioblastoma. Crizotinib is a small molecule tyrosine kinase inhibitor targeting ALK, ROS1, and MET kinases, while temozolomide is an oral alkylating agent that induces DNA damage in tumor cells. The rationale for combining these agents lies in the role of MET-signaling and midkine (an ALK ligand) in promoting glioma cell maintenance and resistance to anticancer therapies; thus, dual inhibition with crizotinib may enhance the efficacy of standard chemoradiotherapy with temozolomide. In clinical studies, this combination has shown a manageable safety profile and encouraging efficacy signals when used alongside radiotherapy in patients with newly diagnosed glioblastoma[1][2][7].
- Other names
- crizotinib + TMZ
02
Targets
DNAALK (Anaplastic lymphoma kinase receptor tyrosine kinase)MET (Mesenchymal-epithelial transition factor receptor)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)
Beyond the preview
Go deeper on crizotinib + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on crizotinib + temozolomide.